Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Reactive astrocytes as therapeutic targets for CNS disorders.
The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vδ1 TCR.
Mountain View Pharmaceuticals receives European patent on potential long-acting drug for multiple sclerosis
Santhera to discontinue sale of Catena® in Canada
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica.
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis.
Good Early Results for HERV Suppressor in MS
Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.
IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.
Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study.
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
Assessment of statistical significance and clinical relevance.
Roche reports positive studies of MabThera given by subcutaneous injection
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.
Cyclophosphamide
Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.
Multiple sclerosis: an immune or neurodegenerative disorder?
Differential roles of microglia and monocytes in the inflamed central nervous system.
Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.
Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.
Ofatumumab
Tumefactive Multiple Sclerosis presenting as Acute Ischemic Stroke.

Pages